Download App

Log in to access Online Inquiry
Company Overview More
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
CEO: Garg Ph.D., Vipin K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > ALT Altimmune > Detailed Quotes

ALT Altimmune

4.840-0.450-8.51%
Close 05/18 20:00 ET
4.84000.00%
Post Mkt Price 05/18 16:01 ET
High
5.350
Open
5.130
Turnover
2.83M
Low
4.800
Pre Close
5.290
Volume
564.26K
Market Cap
209.18M
P/E(TTM)
Loss
52wk High
19.460
Shares
43.22M
P/E(Static)
Loss
52wk Low
3.830
Float Cap
171.43M
Bid/Ask %
60.00%
Historical High
978.000
Shs Float
35.42M
Volume Ratio
0.63
Historical Low
-1731.000
Dividend TTM
--
Div Yield TTM
--
P/B
1.13
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.59%
Amplitude
10.40%
Avg Price
5.016
Lot Size
1
Float Cap
171.43M
Bid/Ask %
60.00%
Historical High
978.000
Shs Float
35.42M
Volume Ratio
0.63
Historical Low
-1731.000
Dividend TTM
--
P/B
1.13
Dividend LFY
--
Turnover Ratio
1.59%
Amplitude
10.40%
Avg Price
5.016
Lot Size
1
Price Forecast

No Data

News

Comment